Market closedNon-fractional
Zentalis Pharmaceuticals/ZNTL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
Ticker
ZNTL
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
New York, United States
Employees
124
Website
zentalis.com
ZNTL Metrics
BasicAdvanced
$310M
Market cap
-
P/E ratio
-$3.20
EPS
1.83
Beta
-
Dividend rate
Price and volume
Market cap
$310M
Beta
1.83
Financial strength
Current ratio
9.194
Quick ratio
8.923
Long term debt to equity
9.289
Total debt to equity
9.886
Management effectiveness
Return on assets (TTM)
-24.93%
Return on equity (TTM)
-51.87%
Valuation
Price to revenue (TTM)
7.343
Price to book
0.67
Price to tangible book (TTM)
0.68
Price to free cash flow (TTM)
-1.411
Growth
Earnings per share change (TTM)
-25.10%
3-year earnings per share growth (CAGR)
-8.03%
What the Analysts think about ZNTL
Analyst Ratings
Majority rating from 11 analysts.
ZNTL Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$41M
∞%
Net income
$10M
-116.42%
Profit margin
24.69%
∞%
ZNTL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.85
-$0.79
-$0.93
$0.14
-
Expected
-$1.04
-$0.91
-$0.92
-$0.77
-$0.86
Surprise
78.31%
-13.35%
1.54%
-118.26%
-
ZNTL News
AllArticlesVideos
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
GlobeNewsWire·11 hours ago
Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm
PRNewsWire·1 day ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
PRNewsWire·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Zentalis Pharmaceuticals stock?
Zentalis Pharmaceuticals (ZNTL) has a market cap of $310M as of July 27, 2024.
What is the P/E ratio for Zentalis Pharmaceuticals stock?
The price to earnings (P/E) ratio for Zentalis Pharmaceuticals (ZNTL) stock is 0 as of July 27, 2024.
Does Zentalis Pharmaceuticals stock pay dividends?
No, Zentalis Pharmaceuticals (ZNTL) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Zentalis Pharmaceuticals dividend payment date?
Zentalis Pharmaceuticals (ZNTL) stock does not pay dividends to its shareholders.
What is the beta indicator for Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals (ZNTL) has a beta rating of 1.83. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Zentalis Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.